SCSerena Ceddia

Serena Ceddia

*This is an algorithmically generated author record based on publicly available information.

Serena Ceddia has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Narrative Medicine: A Digital Diary in the Management of Patients with Bone and Soft Tissue Sarcoma—A Multidisciplinary Pilot Study

    by Maria Cecilia Cercato, Concetta Elisa Onesti, Sabrina Vari, Gabriella Maggi, Wioletta Faltyn, Serena Ceddia, Irene Terrenato, Virginia Scarinci, Francesca Servoli, Cristina Cenci, et al.

    Although patient narratives have been increasingly introduced in various fields of medicine, a standard method in clinical practice is still lacking. The objectives of this pilot study were to evaluate the feasibility and usefulness of a digital narrative diary integrated into the care pathway of patients with bone sarcoma and limb soft tissue sarcoma both from the patients’ and the healthcare professionals’ (HCPs) perspectives. A digital platform, DNMLAB, was designed to obtain guided narratives from patients during their pathway of care in compliance with confidentiality and data protection laws. The diary was used for patients, often young, facing a rare and impactful disease that is difficult to manage and with few opportunities to share experiences. The multidisciplinary team shared the narratives and integrated them into the patient’s treatment pathway. Narrative prompts were adequate for the care pathway. Patients correctly considered the diary as a shared area to think about their condition, and HCPs considered it “a shared area growing at each meeting with the patient”. The main advantages reported by patients were increased awareness, the opportunity to express their opinion on cures and important personal needs and the perception of better taking charge (score ≥ 4.6). The main advantages of HCP were improved communication, therapeutic alliance, and deeper knowledge of patients. This study confirmed the authors’ previous experiences, showing that a digital narrative process is feasible and useful for oncology clinical practice according to patients and HCPs.


  • Open Access

    KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges

    by Serena Ceddia, Lorenza Landi, Federico Cappuzzo

    KRAS is the most frequently mutated oncogene identified in human cancers. Despite the numerous efforts to develop effective specific inhibitors against KRAS, this molecule has remained “undruggable” for decades. The development of direct KRAS inhibitors, such as sotorasib, the first FDA-approved drug targeting KRAS G12C, or adagrasib, was made possible with the discovery of a small pocket in the binding switch II region of KRAS G12C. However, a new challenge is represented by the necessity to overcome resistance mechanisms to KRAS inhibitors. Another area to be explored is the potential role of co-mutations in the selection of the treatment strategy, particularly in the setting of immune checkpoint inhibitors. The aim of this review was to analyze the state-of-the-art of KRAS mutations in non-small-cell lung cancer by describing the biological structure of KRAS and exploring the clinical relevance of KRAS as a prognostic and predictive biomarker. We reviewed the different treatment approaches, focusing on the novel therapeutic strategies for the treatment of KRAS-mutant lung cancers.